Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma

Search this Article

Author(s)

    • TOBINAI Kensei
    • Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital
    • OGURA Michinori
    • Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital
    • ITOH Kuniaki
    • Division of Oncology and Hematology, National Cancer Center Hospital East
    • MORISHIMA Yasuo
    • Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital
    • ANDO Kiyoshi
    • Department of Hematology and Oncology, Tokai University School of Medicine
    • TANIWAKI Masafumi
    • Department of Hematology and Oncology, Kyoto Prefectural University of Medicine
    • WATANABE Takashi
    • Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital
    • UCHIDA Toshiki
    • Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital
    • NAKATA Masanobu
    • Division of Oncology and Hematology, National Cancer Center Hospital East
    • TERAUCHI Takashi
    • Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center
    • NAWANO Shigeru
    • Division of Diagnostic Radiology, National Cancer Center Hospital East

Journal

  • Cancer Sci.

    Cancer Sci. 100(10), 1951-1956, 2009-10-10

References:  34

Cited by:  2

Codes

  • NII Article ID (NAID)
    10027196034
  • NII NACSIS-CAT ID (NCID)
    AA11808050
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    13479032
  • Data Source
    CJP  CJPref 
Page Top